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Summary: FK506 (Prograt) is a new immunosuppressive agent. recently ap-
proved for use in solid organ transplants. The first use of FK506 was for the 
indication of refractory liver allograft rejection. This revealed a marked ability 
to reverse ongoing rejection. even in cases where chronic changes were ob-
served. Between 50 and 70% of patients converted to FK506 had shown im-
provement. In long-term follow-up of patients with chronic rejection. 75% of 
patients were still alive at 3 years following FK506 conversion. and 65% of 
liver allografts were still functioning. FK506 has been compared to cyclospor-
ine in primary liver transplantation. In the three randomized trials. freedom 
from rejection was statistically greater in the FK506-treated group, as com-
pared to the cyclosporine-treated group. By intent-to-treat analysis, the patient 
and graft survival in the FK506 group was the same or better than the cyclo-
sporine group. The good results in the cyclosporine limb was due. in part, to 
the ability of FK506 to treat rejection in the cyclosporine group. Freedom from 
steroid use, and the lower incidence of hypertension, were prominent features 
of FK506 patients. FK506 has been used for rescue of rejecting kidney al-
lografts, with results similar to the liver transplant trials. When used as primary 
immunosuppression. FK506 was shown to be effective. as measured by graft 
survival. FK506-based immunosuppression has also been used in primary 
heart transplantation. as well as for primary adult pulmonary transplantation. 
Results from these small series of patients are equally encouraging. The results 
. of these studies suggest that FK506 is effective for solid organ transplantation. 
Both FK506 and cyclosporine administration have been associated with side 
effects. many of which are similar. and some of which are peculiar to a given 
organ transplant. Key Words: Tacrolimus-FK506-Solid organ transplanta-
tion. 
FK506 (Prograt), a macrolide antibiotic produced 
by the fungus Streptomyces tsukubaensis is a new 
immunosuppressive agent (1-4). The first clinical 
use of FK506 was for the indication of uncontrolled 
liver allograft rejection. which was therefore con-
sidered treatment failure of conventional immuno-
suppression (5-11). The results of this experience 
revealed a marked ability to reverse ongoing rejec-
tion, even in cases where chronic changes were ob-
served. Between 50 and 70% of patients treated by 
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conversion to FK506 had both clinical and histo-
pathologic improvement. In a recent long-term fol-
low-up of 113 patients with chronic rejection. 75% 
of patients were still alive at 3 years following 
FK506 conversion, and 65% of liver allografts were 
still functioning (8). 
Following an initial experience with FK506 as 
primary immunosuppression following liver trans-
plantation at the University of Pittsburgh (12,13), 
FK506 has been compared to cyclosporine in pri-
mary liver transplantation, in randomized, non-
blinded studies. At the University of Pittsburgh, 
low-risk candidates were randomized to FK506 
with steroids as compared with cyclosporine with 
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steroids (14.15). One hundred fifty-four patients 
were studied. and the I-year patient and graft sur-
vival, as analyzed by intent to treat, was 92 and 
88%, respectively, for FK506, compared with 85% 
and 79%, respectively, for cyclosporine. The fol-
low-up at 2 years revealed that the modest increase 
in patient and graft survival in the FK506 limb was 
retained. The good results in the cyclosporine limb 
was due, in part, to the ability of FK506 to treat 
rejection in the cyclosporine group. The freedom 
from rejection was statistically greater in the 
FK506-treated group. as compared with the cyclo-
sporine-treated group. In addition, the freedom 
from steroid use, and the lower incidence of hyper-
tension. were prominent features of patients treated 
with FK506. The subsequent conversion of baseline 
immunosuppression from CsA-based regimens to 
FK506 at the .University of Pittsburgh was associ-
ated with significant improvement in both patient 
and graft survival. when compared with immedi-
ately preceding eras of CsA based therapies (16). 
The results of the University of Pittsburgh studies 
compare favorably to two other randomized liver 
transplant trials in both the United States and Eu-
rope 07.18). In each series, >500 patients were en-
tered into the combined FK506 and CsA limbs. 
Both trials utilized a regimented FK506 treatment 
arm. although at higher initial FK506 dosages than 
have been utilized at the University of Pittsburgh. 
The European study demonstrated an enhanced pa-
tient and graft survival in the FK506 limb, when 
compared with the CsA limb. although this did not 
reach statistically significant difference. Although 
patient survival was similar in both groups in the 
American study. there was a slight benefit in graft 
survival in the FK506 limb. In both studies. there 
was less rejection in the FK506 limb. and the over-
all dose of steroids was less in the FK506 limb. By 
protocol design. crossover from CsA to FK506 was 
allowed for refractory rejection. while crossover 
from FK506 to CsA was allowed for adverse events 
in the FK506 limb only. With these conditions, the 
refractory rejection rates in the European study for 
PKs06 was 2.9%. whereas that for the CsA limb was 
10.4%. In the American study. the corresponding 
rates of refractory rejection was 3.0 and 14.8%, re-
Spectively. The differences in refractory rejection 
were significantly different. and the majority ofCsA 
I'tfractory rejections were rescued by conversion to 
PKs06. The ability of FK506 to rescue CsA failures 
9Ias the major reason that the survival in the CsA limb 
9Ias retained at levels equivalent to the FK506limb. 
The application of FK506 rescue therapy to kid-
ney transplantation was an extension of the experi-
ence gained in liver transplantation (19,20). The 
main difference between the two organ systems is 
the predominance of arteriopathy and sclerosis of 
epithelial structures in the kidney allografts under-
going chronic rejection. This was found to limit the 
ability of FK506 to rescue grafts with this patholog-
ic finding. In a series of 35 patients. those with on-
going acute cellular rejection had a successful con-
version rate of 71 %. whereas those with stigmata of 
chronic rejection w<:;re not able to be rescued. 
Those with living related kidney transplants had a 
higher rate of rescue (73%) as compared with those 
with cadaver grafts (50%), probably related to an 
earlier referral for FK506 rescue therapy. 
A randomized trial, utilizing FK506 in a double 
drug regimen (FK506 and steroids) versus a triple 
drug regimen (FK506, steroids. and azathioprine), 
was performed in kidney transplantation at the Uni-
versity of Pittsburgh (21). Two hundred four pa-
tients were enrolled; there were no specific exclu-
sion criteria based on immunologic or transplant 
history. The I-year actuarial patient and graft sur-
vival for the two-drug versus three-drug regimen 
were 95 and 90% versus 91 and 82%, respectively. 
No differences were noted in kidney function with 
mean serum creatinine of 1.8 ± 0.8 mgldl. The re-
jection rate in the three-drug regimen was less than 
that for the two-drug regimen (10% vs. 51%), al-
though this was not statistically significant (p = 
0.07). Crossover from one group to another was not 
uncommon, 25% of the two-drug group were given 
azathioprine. principally because of rejection, 
whereas 45% of the three-drug group required dis-
continuation of azathioprine because of leucopenia 
or hepatic dysfunction. 
FK506-based immunosuppression has also been 
used in heart transplantation at the University of 
Pittsburgh (22). Seventy-two adult patients were 
given FK506 as primary immunosuppression fol-
lowing heart transplantation. The I-year patient and 
graft survival was 92%. The freedom from rejection 
at 90 days was 41% and at 180 days was 34%. Renal 
dysfunction was frequently noted, and the mean se-
rum creatinine at 6 months following transplanta-
tion was 2.2 mgldl. The incidence of diastolic hy-
pertension was 54%. but was considered mild. as 
treatment consisted of a single agent in all cases. 
The incidence of new onset diabetes was 20% in this 
group of patients. 
A prospective randomized trial of primary adult 
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pulmonary transplantation was conducted at the 
University of Pittsburgh (23). Azathioprine was 
combined with either FK506 or cyclosporine. with 
use of steroids only if the recipient encountered 
more than one episode of rejection. Twenty-eight 
patients were randomized to FK506 and 29 patients 
were randomized to cyclosporine. The 6-month 
graft survival was statistically better in the FK506 
group as compared with the cyclosporine group (86 
vs. 69% respectively; p < 0.05). Twenty-one per-
cent of the FK506 patients were rejection free at 6 
months. as compared with only 3% of the cyclo-
sporine patients. 
One way to assess the impact of a new immuno-
suppressive agent in transplantation is the ability to 
successfully transplant organs that was not consid-
ered feasible with standard immunosuppression. 
Success with intestinal transplantation under cyclo-
sporine immunosuppression has been sporadic (24-
26). A growing experience of small bowel transplan-
tation. either alone. or combined with other abdom-
inal organs. has been accumulated under FK506 at 
the University of Pittsburgh (27-30). Small bowel 
allografts have been transplanted alone (n = 9), to-
gether with liver (n = 16), or as part of a multivis-
ceral cluster (n = 3). In these 28 patients, 82% were 
alive at a median follow-up of 9 months. Graft sur-
vival was 76% for the same period of time. Graft 
function was satisfactory, with 84% of survivors be-
ing totally enteraIly sufficient and the other 16% 
relying on supplemental parenteral nutrition. Rejec-
tion was not uncommon, with 90% of the patients 
having at least one rejection episode of the intesti-
nal allograft. Rejection has been treated by addi-
tional steroids and addition of azathioprine; how-
ever, antilymphocyte preparations have been used 
occasionally. 
The results of these studies suggest that FK506 is 
effective for solid organ transplantation. Neverthe-
less, FK506 is not without its limitations. Toxicity 
profiles for FK506 are similar to that for cyclospor-
ine, perhaps because of similar mechanisms of ac-
tion (31). Both FK506 and cyclosporine administra-
tion have been associated with side effects, many of 
which are similar, and some of which are peculiar to 
a given organ transplant (32,33). Adverse reactions 
requiring treatment or adjustment of FK506 doses 
can be categorized into four primary areas. These 
are (a) alterations in kidney function, (b) alterations 
in glucose metabolism, (c) neurotoxicity, and (d) 
susceptibility to infection or malignancy. 
One of the major benefits of FK506 appears to be 
qh~r Drug Monit. Vol. 17. No.6. 1995 
a relative lack of some of the side effects of cyclo-
sporine. Some of these are cosmetic. such as hir-
sutism and gingival hyperplasia. which has not been 
seen with FK506. Other more significant side ef-
fects. such as hypertension. appear to be less in the 
FK506 patients than in those on cyclosporine. The 
ability to use less steroids in patients with FK506. 
when compared with cyclosporine. may result in 
less complications ascribed to chronic steroid use. 
In one study where FK506 was compared with cy-
c1osporine in pediatric renal transplant recipients. 
78% of all FK506 recipients were off steroids. Sig-
nificant improvement in the growth pattern of pre-
adolescents on FK506 monotherapy was noted 
when compared with those on FK506 and steroids 
or cyclosporine and steroids. 
The primary side effects of FK506. are insomnia, 
tremors. headaches. tingling sensations. muscle 
achiness. itching. fatigue. visual sensitivity to light. 
and GI symptoms. Although it has taken> 10 years 
to elucidate the limitations of cyclosporine therapy. 
we believe that the profile of adverse effects of 
FK506 has been determined. Schemes to minimize 
these effects should increase the safety of this agent 
for immunosuppression. 
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